What is the current valuation of the Neuropsychiatric Disorders Treatment Market?

The market valuation was 145.03 USD Billion in 2024. Read More

What is the projected market size for the Neuropsychiatric Disorders Treatment Market by 2035?

The projected valuation for 2035 is 422.21 USD Billion. Read More

What is the expected CAGR for the Neuropsychiatric Disorders Treatment Market during the forecast period?

The expected CAGR for the market from 2025 to 2035 is 10.2%. Read More

Which treatment types dominate the Neuropsychiatric Disorders Treatment Market?

Pharmacological Treatment leads with a valuation of 58.01 USD Billion in 2024. Read More

How does the market perform in terms of disorder types?

Depression accounted for 40.0 USD Billion in 2024, making it a leading disorder type. Read More

What are the key demographics for patients in the Neuropsychiatric Disorders Treatment Market?

Adults represented the largest demographic with a valuation of 70.0 USD Billion in 2024. Read More

What administration routes are prevalent in the Neuropsychiatric Disorders Treatment Market?

Oral administration was the most common route, valued at 58.01 USD Billion in 2024. Read More

Which companies are considered key players in the Neuropsychiatric Disorders Treatment Market?

Key players include Johnson & Johnson, Pfizer, and Eli Lilly and Company, among others. Read More

What is the market valuation for psychotherapy as a treatment type?

Psychotherapy was valued at 36.02 USD Billion in 2024. Read More

How does the market for behavioral disorders compare to other therapeutic areas?

Behavioral Disorders had a valuation of 45.03 USD Billion in 2024, indicating strong market presence. Read More

Neuropsychiatric Disorders Treatment Market

Neuropsychiatric Disorders and Treatment Market Research Report Information By Disorders (Degenerative Diseases, Neurotic Disorders, Psychosis, and Others), By Treatment (Shock Treatment, Drug Treatment, and Others), By End User (Hospitals, Clinics, Research Centres, and Others), And By Region (North America, Europe, Asia-Pacific, and Rest Of The World) –Market Forecast Till 2035

Forecast Period

2025 - 2035

CAGR

10.2%

2024 Market Size

$ 145.03 Billion

2035 Market Size

$ 422.21 Billion

Pharmaceutical ● Updated August 2026 Report ID: MRFR/Pharma/0773-HCR | Pages: 80 | Author: Satyendra Maurya, Kinjoll Dey

Summary Table of Contents Segmentation Methodology Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Treatment Type (USD Billion)
  1. 4.1.1 Pharmacological Treatment
  2. 4.1.2 Psychotherapy
  3. 4.1.3 Electroconvulsive Therapy
  4. 4.1.4 Transcranial Magnetic Stimulation
  5. 4.1.5 Neurofeedback
2. 4.2 Healthcare, BY Disorder Type (USD Billion)
  1. 4.2.1 Depression
  2. 4.2.2 Anxiety Disorders
  3. 4.2.3 Bipolar Disorder
  4. 4.2.4 Schizophrenia
  5. 4.2.5 Obsessive-Compulsive Disorder
3. 4.3 Healthcare, BY Patient Demographics (USD Billion)
  1. 4.3.1 Children
  2. 4.3.2 Adolescents
  3. 4.3.3 Adults
  4. 4.3.4 Elderly
  5. 4.3.5 Gender-Specific
4. 4.4 Healthcare, BY Administration Route (USD Billion)
  1. 4.4.1 Oral
  2. 4.4.2 Intravenous
  3. 4.4.3 Intramuscular
  4. 4.4.4 Transdermal
  5. 4.4.5 Inhalation
5. 4.5 Healthcare, BY Therapeutic Area (USD Billion)
  1. 4.5.1 Mood Disorders
  2. 4.5.2 Anxiety Disorders
  3. 4.5.3 Psychotic Disorders
  4. 4.5.4 Cognitive Disorders
  5. 4.5.5 Behavioral Disorders
6. 4.6 Healthcare, BY Region (USD Billion)
  1. 4.6.1 North America
    1. 4.6.1.1 US
    2. 4.6.1.2 Canada
  2. 4.6.2 Europe
    1. 4.6.2.1 Germany
    2. 4.6.2.2 UK
    3. 4.6.2.3 France
    4. 4.6.2.4 Russia
    5. 4.6.2.5 Italy
    6. 4.6.2.6 Spain
    7. 4.6.2.7 Rest of Europe
  3. 4.6.3 APAC
    1. 4.6.3.1 China
    2. 4.6.3.2 India
    3. 4.6.3.3 Japan
    4. 4.6.3.4 South Korea
    5. 4.6.3.5 Malaysia
    6. 4.6.3.6 Thailand
    7. 4.6.3.7 Indonesia
    8. 4.6.3.8 Rest of APAC
  4. 4.6.4 South America
    1. 4.6.4.1 Brazil
    2. 4.6.4.2 Mexico
    3. 4.6.4.3 Argentina
    4. 4.6.4.4 Rest of South America
  5. 4.6.5 MEA
    1. 4.6.5.1 GCC Countries
    2. 4.6.5.2 South Africa
    3. 4.6.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Johnson & Johnson (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Pfizer (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Eli Lilly and Company (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 AstraZeneca (GB)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Bristol-Myers Squibb (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Novartis (CH)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Sanofi (FR)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 AbbVie (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Otsuka Pharmaceutical (JP)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY TREATMENT TYPE
4. 6.4 US MARKET ANALYSIS BY DISORDER TYPE
5. 6.5 US MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6. 6.6 US MARKET ANALYSIS BY ADMINISTRATION ROUTE
7. 6.7 US MARKET ANALYSIS BY THERAPEUTIC AREA
8. 6.8 CANADA MARKET ANALYSIS BY TREATMENT TYPE
9. 6.9 CANADA MARKET ANALYSIS BY DISORDER TYPE
10. 6.10 CANADA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
11. 6.11 CANADA MARKET ANALYSIS BY ADMINISTRATION ROUTE
12. 6.12 CANADA MARKET ANALYSIS BY THERAPEUTIC AREA
13. 6.13 EUROPE MARKET ANALYSIS
14. 6.14 GERMANY MARKET ANALYSIS BY TREATMENT TYPE
15. 6.15 GERMANY MARKET ANALYSIS BY DISORDER TYPE
16. 6.16 GERMANY MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
17. 6.17 GERMANY MARKET ANALYSIS BY ADMINISTRATION ROUTE
18. 6.18 GERMANY MARKET ANALYSIS BY THERAPEUTIC AREA
19. 6.19 UK MARKET ANALYSIS BY TREATMENT TYPE
20. 6.20 UK MARKET ANALYSIS BY DISORDER TYPE
21. 6.21 UK MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
22. 6.22 UK MARKET ANALYSIS BY ADMINISTRATION ROUTE
23. 6.23 UK MARKET ANALYSIS BY THERAPEUTIC AREA
24. 6.24 FRANCE MARKET ANALYSIS BY TREATMENT TYPE
25. 6.25 FRANCE MARKET ANALYSIS BY DISORDER TYPE
26. 6.26 FRANCE MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
27. 6.27 FRANCE MARKET ANALYSIS BY ADMINISTRATION ROUTE
28. 6.28 FRANCE MARKET ANALYSIS BY THERAPEUTIC AREA
29. 6.29 RUSSIA MARKET ANALYSIS BY TREATMENT TYPE
30. 6.30 RUSSIA MARKET ANALYSIS BY DISORDER TYPE
31. 6.31 RUSSIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
32. 6.32 RUSSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
33. 6.33 RUSSIA MARKET ANALYSIS BY THERAPEUTIC AREA
34. 6.34 ITALY MARKET ANALYSIS BY TREATMENT TYPE
35. 6.35 ITALY MARKET ANALYSIS BY DISORDER TYPE
36. 6.36 ITALY MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
37. 6.37 ITALY MARKET ANALYSIS BY ADMINISTRATION ROUTE
38. 6.38 ITALY MARKET ANALYSIS BY THERAPEUTIC AREA
39. 6.39 SPAIN MARKET ANALYSIS BY TREATMENT TYPE
40. 6.40 SPAIN MARKET ANALYSIS BY DISORDER TYPE
41. 6.41 SPAIN MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
42. 6.42 SPAIN MARKET ANALYSIS BY ADMINISTRATION ROUTE
43. 6.43 SPAIN MARKET ANALYSIS BY THERAPEUTIC AREA
44. 6.44 REST OF EUROPE MARKET ANALYSIS BY TREATMENT TYPE
45. 6.45 REST OF EUROPE MARKET ANALYSIS BY DISORDER TYPE
46. 6.46 REST OF EUROPE MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
47. 6.47 REST OF EUROPE MARKET ANALYSIS BY ADMINISTRATION ROUTE
48. 6.48 REST OF EUROPE MARKET ANALYSIS BY THERAPEUTIC AREA
49. 6.49 APAC MARKET ANALYSIS
50. 6.50 CHINA MARKET ANALYSIS BY TREATMENT TYPE
51. 6.51 CHINA MARKET ANALYSIS BY DISORDER TYPE
52. 6.52 CHINA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
53. 6.53 CHINA MARKET ANALYSIS BY ADMINISTRATION ROUTE
54. 6.54 CHINA MARKET ANALYSIS BY THERAPEUTIC AREA
55. 6.55 INDIA MARKET ANALYSIS BY TREATMENT TYPE
56. 6.56 INDIA MARKET ANALYSIS BY DISORDER TYPE
57. 6.57 INDIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
58. 6.58 INDIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
59. 6.59 INDIA MARKET ANALYSIS BY THERAPEUTIC AREA
60. 6.60 JAPAN MARKET ANALYSIS BY TREATMENT TYPE
61. 6.61 JAPAN MARKET ANALYSIS BY DISORDER TYPE
62. 6.62 JAPAN MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
63. 6.63 JAPAN MARKET ANALYSIS BY ADMINISTRATION ROUTE
64. 6.64 JAPAN MARKET ANALYSIS BY THERAPEUTIC AREA
65. 6.65 SOUTH KOREA MARKET ANALYSIS BY TREATMENT TYPE
66. 6.66 SOUTH KOREA MARKET ANALYSIS BY DISORDER TYPE
67. 6.67 SOUTH KOREA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
68. 6.68 SOUTH KOREA MARKET ANALYSIS BY ADMINISTRATION ROUTE
69. 6.69 SOUTH KOREA MARKET ANALYSIS BY THERAPEUTIC AREA
70. 6.70 MALAYSIA MARKET ANALYSIS BY TREATMENT TYPE
71. 6.71 MALAYSIA MARKET ANALYSIS BY DISORDER TYPE
72. 6.72 MALAYSIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
73. 6.73 MALAYSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
74. 6.74 MALAYSIA MARKET ANALYSIS BY THERAPEUTIC AREA
75. 6.75 THAILAND MARKET ANALYSIS BY TREATMENT TYPE
76. 6.76 THAILAND MARKET ANALYSIS BY DISORDER TYPE
77. 6.77 THAILAND MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
78. 6.78 THAILAND MARKET ANALYSIS BY ADMINISTRATION ROUTE
79. 6.79 THAILAND MARKET ANALYSIS BY THERAPEUTIC AREA
80. 6.80 INDONESIA MARKET ANALYSIS BY TREATMENT TYPE
81. 6.81 INDONESIA MARKET ANALYSIS BY DISORDER TYPE
82. 6.82 INDONESIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
83. 6.83 INDONESIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
84. 6.84 INDONESIA MARKET ANALYSIS BY THERAPEUTIC AREA
85. 6.85 REST OF APAC MARKET ANALYSIS BY TREATMENT TYPE
86. 6.86 REST OF APAC MARKET ANALYSIS BY DISORDER TYPE
87. 6.87 REST OF APAC MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
88. 6.88 REST OF APAC MARKET ANALYSIS BY ADMINISTRATION ROUTE
89. 6.89 REST OF APAC MARKET ANALYSIS BY THERAPEUTIC AREA
90. 6.90 SOUTH AMERICA MARKET ANALYSIS
91. 6.91 BRAZIL MARKET ANALYSIS BY TREATMENT TYPE
92. 6.92 BRAZIL MARKET ANALYSIS BY DISORDER TYPE
93. 6.93 BRAZIL MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
94. 6.94 BRAZIL MARKET ANALYSIS BY ADMINISTRATION ROUTE
95. 6.95 BRAZIL MARKET ANALYSIS BY THERAPEUTIC AREA
96. 6.96 MEXICO MARKET ANALYSIS BY TREATMENT TYPE
97. 6.97 MEXICO MARKET ANALYSIS BY DISORDER TYPE
98. 6.98 MEXICO MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
99. 6.99 MEXICO MARKET ANALYSIS BY ADMINISTRATION ROUTE
100. 6.100 MEXICO MARKET ANALYSIS BY THERAPEUTIC AREA
101. 6.101 ARGENTINA MARKET ANALYSIS BY TREATMENT TYPE
102. 6.102 ARGENTINA MARKET ANALYSIS BY DISORDER TYPE
103. 6.103 ARGENTINA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
104. 6.104 ARGENTINA MARKET ANALYSIS BY ADMINISTRATION ROUTE
105. 6.105 ARGENTINA MARKET ANALYSIS BY THERAPEUTIC AREA
106. 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT TYPE
107. 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISORDER TYPE
108. 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
109. 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY ADMINISTRATION ROUTE
110. 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY THERAPEUTIC AREA
111. 6.111 MEA MARKET ANALYSIS
112. 6.112 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT TYPE
113. 6.113 GCC COUNTRIES MARKET ANALYSIS BY DISORDER TYPE
114. 6.114 GCC COUNTRIES MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
115. 6.115 GCC COUNTRIES MARKET ANALYSIS BY ADMINISTRATION ROUTE
116. 6.116 GCC COUNTRIES MARKET ANALYSIS BY THERAPEUTIC AREA
117. 6.117 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT TYPE
118. 6.118 SOUTH AFRICA MARKET ANALYSIS BY DISORDER TYPE
119. 6.119 SOUTH AFRICA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
120. 6.120 SOUTH AFRICA MARKET ANALYSIS BY ADMINISTRATION ROUTE
121. 6.121 SOUTH AFRICA MARKET ANALYSIS BY THERAPEUTIC AREA
122. 6.122 REST OF MEA MARKET ANALYSIS BY TREATMENT TYPE
123. 6.123 REST OF MEA MARKET ANALYSIS BY DISORDER TYPE
124. 6.124 REST OF MEA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
125. 6.125 REST OF MEA MARKET ANALYSIS BY ADMINISTRATION ROUTE
126. 6.126 REST OF MEA MARKET ANALYSIS BY THERAPEUTIC AREA
127. 6.127 KEY BUYING CRITERIA OF HEALTHCARE
128. 6.128 RESEARCH PROCESS OF MRFR
129. 6.129 DRO ANALYSIS OF HEALTHCARE
130. 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE
131. 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
132. 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE
133. 6.133 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE)
134. 6.134 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Billion)
135. 6.135 HEALTHCARE, BY DISORDER TYPE, 2024 (% SHARE)
136. 6.136 HEALTHCARE, BY DISORDER TYPE, 2024 TO 2035 (USD Billion)
137. 6.137 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE)
138. 6.138 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Billion)
139. 6.139 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 (% SHARE)
140. 6.140 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Billion)
141. 6.141 HEALTHCARE, BY THERAPEUTIC AREA, 2024 (% SHARE)
142. 6.142 HEALTHCARE, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Billion)
143. 6.143 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.2.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
  3. 7.2.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  4. 7.2.4 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  5. 7.2.5 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.3.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
  3. 7.3.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  4. 7.3.4 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  5. 7.3.5 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.4.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
  3. 7.4.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  4. 7.4.4 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  5. 7.4.5 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.5.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
  3. 7.5.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  4. 7.5.4 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  5. 7.5.5 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.6.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
  3. 7.6.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  4. 7.6.4 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  5. 7.6.5 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.7.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
  3. 7.7.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  4. 7.7.4 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  5. 7.7.5 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.8.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
  3. 7.8.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  4. 7.8.4 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  5. 7.8.5 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.9.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
  3. 7.9.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  4. 7.9.4 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  5. 7.9.5 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.10.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
  3. 7.10.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  4. 7.10.4 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  5. 7.10.5 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.11.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
  3. 7.11.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  4. 7.11.4 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  5. 7.11.5 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.12.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
  3. 7.12.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  4. 7.12.4 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  5. 7.12.5 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.13.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
  3. 7.13.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  4. 7.13.4 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  5. 7.13.5 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.14.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
  3. 7.14.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  4. 7.14.4 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  5. 7.14.5 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.15.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
  3. 7.15.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  4. 7.15.4 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  5. 7.15.5 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.16.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
  3. 7.16.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  4. 7.16.4 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  5. 7.16.5 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.17.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
  3. 7.17.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  4. 7.17.4 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  5. 7.17.5 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.18.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
  3. 7.18.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  4. 7.18.4 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  5. 7.18.5 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.19.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
  3. 7.19.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  4. 7.19.4 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  5. 7.19.5 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.20.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
  3. 7.20.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  4. 7.20.4 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  5. 7.20.5 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.21.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
  3. 7.21.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  4. 7.21.4 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  5. 7.21.5 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.22.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
  3. 7.22.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  4. 7.22.4 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  5. 7.22.5 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.23.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
  3. 7.23.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  4. 7.23.4 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  5. 7.23.5 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.24.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
  3. 7.24.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  4. 7.24.4 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  5. 7.24.5 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.25.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
  3. 7.25.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  4. 7.25.4 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  5. 7.25.5 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.26.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
  3. 7.26.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  4. 7.26.4 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  5. 7.26.5 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.27.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
  3. 7.27.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  4. 7.27.4 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  5. 7.27.5 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.28.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
  3. 7.28.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  4. 7.28.4 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  5. 7.28.5 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.29.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
  3. 7.29.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  4. 7.29.4 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  5. 7.29.5 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.30.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
  3. 7.30.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  4. 7.30.4 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  5. 7.30.5 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Neuropsychiatric Disorders Treatment Market Segmentation

Neuropsychiatric Disorders Treatment Market By Treatment Type (USD Billion, 2025-2035)

Pharmacological Treatment
Psychotherapy
Electroconvulsive Therapy
Transcranial Magnetic Stimulation
Neurofeedback

Neuropsychiatric Disorders Treatment Market By Disorder Type (USD Billion, 2025-2035)

Depression
Anxiety Disorders
Bipolar Disorder
Schizophrenia
Obsessive-Compulsive Disorder

Neuropsychiatric Disorders Treatment Market By Patient Demographics (USD Billion, 2025-2035)

Children
Adolescents
Adults
Elderly
Gender-Specific

Neuropsychiatric Disorders Treatment Market By Administration Route (USD Billion, 2025-2035)

Oral
Intravenous
Intramuscular
Transdermal
Inhalation

Neuropsychiatric Disorders Treatment Market By Therapeutic Area (USD Billion, 2025-2035)

Mood Disorders
Anxiety Disorders
Psychotic Disorders
Cognitive Disorders
Behavioral Disorders

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”

Guilherme Gomes Martins Product Management Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035